FDA approves Rituxan to treat two rare disorders

Posted by Food and Drug Administration--Press Releases on Tuesday Apr 19, 2011 Under News

The U.S. Food and Drug Administration today approved Rituxan (rituximab), in combination with glucocorticoids (steroids), to treat patients with Wegener’s granulomatosis (WG) and microscopic polyangiitis (MPA), two rare disorders that cause blood vessel inflammation (vasculitis).

Comments are closed.